Results 41 to 50 of about 20,867 (266)
Chronic Diseases and Translational Medicine, EarlyView.Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig +7 more
wiley +1 more source
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass [PDF]
Diabetes & Metabolism Journal, 2016 Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized
Suk Chon, Jean-François Gautier
doaj +1 more source
Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics
Chemistry – A European Journal, EarlyView.A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova +11 more
wiley +1 more source
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Cells, 2023 Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control ...
Sydney S. Wilbon, Mikhail G. Kolonin
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Bridget L. Morse +7 more
wiley +1 more source
Equine Veterinary Journal, EarlyView.Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source
A New Vista of Opportunity in Diabetes Management: Natural Product‐Based β‐cell Preservation
Food Chemistry International, EarlyView.Preserving functional β‐cells via natural products offers promising strategy for diabetes treatment. ABSTRACT A defining characteristic of diabetes is β‐cell failure, in which β‐cells cannot modulate insulin secretion to compensate for escalating insulin resistance, pushing forward disease development.
Yi‐San Lee +4 more
wiley +1 more source
Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits [PDF]
European Medical Journal Diabetes, 2015 Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are
Daisuke Yabe +3 more
doaj
Food Safety and Health, EarlyView.Psidium guajava leaves contain potent bioactive compounds like quercetin, myricetin, and triterpenoids that show antioxidant, antidiabetic, anti‐inflammatory, and anticancer effects. They act by modulating NF‐κB, PPARγ, and α‐glucosidase and by inducing apoptosis and cell cycle arrest.
Muhammad Waqar +10 more
wiley +1 more source
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
Diabetes, Metabolic Syndrome and Obesity, 2010 Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes.
Kushner P
doaj